Novartis India Ltd. News and Updates

Keep track of all breaking news on Novartis India Ltd. from all sources in a single place.

Load latest

Novartis India Ltd.

24 Feb 2023

842.00

6.79%

India needs regulatory data protection for drug research: Novartis CEO

Business Standard

India should have a regulatory data protection system in place to attract fundamental drug research from major pharmaceutical companies in the world, Novartis Chief Executive Officer Vasant Narasimhan said on Friday here. Speaking to reporters on the sidelines of the life sciences conclave 'BioAsia 2023' being held here, Narasimhan said great work has been done to streamline Intellectual Property (IP) issues which can be further improved. "I think the next step is when you think about how we generate data and how protected that is in regulatory filings. India does not have regulatory data protection," he said replying to a query. If one looks at any place in the world where there is significant fundamental drug research happening from multinational firms, there is regulatory data protection, including China, Narasimhan further said. The Novartis CEO added that getting approvals for clinical trials used to be very difficult in India earlier. However, with the new policy, the process

Novartis India Ltd. is trading below its 100 day SMA of 922.7

India needs regulatory data protection to attract basic pharma research: Novartis CEO

Business Line | 24 Feb 2023

Novartis India Ltd.

22 Feb 2023

842.00

6.79%

Biotech can become a powerhouse in India'

livemint

Novartis CEO Vasant Narasimhan on the impossible odds of drug discovery, R&D and India's regulatory regime

Novartis India Ltd. is trading above its 50 day SMA of 832.4

Novartis India Ltd.

05 Dec 2022

842.00

6.79%

Price war begins for Novartis cardiac drug as JB Pharma cuts rate by 50%

Business Standard

Azmarda will now be sold for Rs 39.6 per tablet for the 50 mg variant, down from Rs 78 per tablet earlier

Novartis India Ltd.'s price crossed above 50Day SMA today

Price war for Novartis cardiac drug begins as JB Pharma implements 50% cut

Business Standard | 05 Dec 2022

Novartis India Ltd.

10 Nov 2022

842.00

6.79%

Novartis India Standalone September 2022 Net Sales at Rs 101.52 crore, down 2.83% Y-o-Y

Moneycontrol

NULL

Novartis India Ltd. is trading above its 50 day SMA of 832.4

Novartis India Ltd.

25 Aug 2022

842.00

6.79%

Novartis to spin off generics business Sandoz next year

Moneycontrol

Novartis (NOVN.S) announced on Thursday that it intended to spin off its generics division Sandoz in order to narrow its focus on its patented prescription drugs.

Novartis India Ltd. is trading at high volume of 61033.00000 with price gain of 6.79.

Novartis India Ltd.

07 Aug 2022

842.00

6.79%

Telangana baby with rare genetic disease administered Rs 16-cr drug

Business Standard

A 23-month-old baby with Spinal Muscular Atrophy (SMA) Type 1, received a new lease of life with Swiss drugmaker Novartis coming forward to donate gene therapy costing Rs 16 crore.

Novartis India Ltd.'s price crossed above 30Day SMA today

Novartis India Ltd.

29 Jun 2022

842.00

6.79%

Pharma major Novartis to slash 8,000 jobs globally

Business Today

The job cuts, previously projected by Chief Executive Vas Narasimhan to be in the "single-digit thousands", are part of a restructuring programme the Swiss pharmaceutical group announced in April, targeting savings of at least $1 billion by 2024.

Novartis India Ltd.'s price crossed above 30Day SMA today

Novartis to cut up to 8,000 jobs globally to save $1 bn by 2024

Business Standard | 28 Jun 2022

Novartis India Ltd.

20 May 2022, 12:00PM

842.00

6.79%

Novartis India Standalone March 2022 Net Sales at Rs 98.32 crore, down 0.98% Y-o-Y

Moneycontrol

NULL

Novartis India Ltd. is trading at high volume of 61033.00000 with price gain of 6.79.

Novartis India Ltd.

11 Feb 2022

842.00

6.79%

Novartis India Standalone December 2021 Net Sales at Rs 98.96 crore, up 5.53% Y-o-Y

Moneycontrol

NULL

Novartis India Ltd.'s price crossed above 30Day SMA today

Novartis India Ltd.

18 Jan 2022

842.00

6.79%

Novartis CEO sees better place' with Covid by year-end

livemint

This may be the year when the world comes to terms with the persistent reality of Covid-19 and reaches a new sense of normalcy, Novartis CEO Vas Narasimhan said

Novartis India Ltd. is trading above its 50 day SMA of 832.4

No results found

Is Novartis India Ltd. worth buying?

61 Votes:

Buy 72.13%

Sell 16.39%

Hold 11.48%

New 52W Low in past week

High volume+gain today

Novartis India Ltd. News and Updates

Keep track of all breaking news on Novartis India Ltd. from all sources in a single place.